At what enterprise value was EUROBIO SCIENTIFIC acquired in 2024?

During the acquisition of EUROBIO SCIENTIFIC by NEXTSTAGE / IK PARTNERS in 2024, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 100M - 350M EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.8x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of EUROBIO SCIENTIFIC when it was acquired by NEXTSTAGE / IK PARTNERS?

The estimated EV/EBITDA multiple for EUROBIO SCIENTIFIC is in the range of 10x - 18x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.8x. Join our community for free to access full valuation data and industry trends.

When was EUROBIO SCIENTIFIC acquired by NEXTSTAGE / IK PARTNERS?

EUROBIO SCIENTIFIC was acquired by NEXTSTAGE / IK PARTNERS in 2024.

What was the revenue of EUROBIO SCIENTIFIC at the time of the deal?

The revenue of EUROBIO SCIENTIFIC at the time of the deal is estimated to be in the range of 100M - 200M EUR. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of EUROBIO SCIENTIFIC during the acquisition?

EUROBIO SCIENTIFIC's EBITDA is estimated to be in the range of 5M - 25M EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the EUROBIO SCIENTIFIC acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the EUROBIO SCIENTIFIC deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://nextstage-am.com/communique-de-presse-eurobio-scientific-eb-development-obtient-une-tres-large-majorite-du-capital-avec-889-detenus-a-lissue-de-loffre-reouverte-pour-poursuivre-son-developpement/

← DATABASE

Home Database Healthcare & PharmaEUROBIO SCIENTIFIC

12/2024

EUROBIO SCIENTIFIC acquired by NEXTSTAGE & IK PARTNERS

FRANCE Life Sciences / Medical Devices / Diagnostic Equipment EV 100M - 350M EUR

Context

EB Development (Consortium: NextStage AM & IK Partners) has successfully concluded its takeover bid for Eurobio Scientific, following the results of a reopened offer period. The consortium now holds 88.92% of the share capital and voting rights (including treasury shares). The offer was initiated to take the company private and provide the management team, led by Denis Fortier, with the flexibility to pursue an aggressive external growth strategy. While the bid secured a significant majority, the final participation fell just short of the 90% threshold required for a mandatory squeeze-out (retrait obligatoire). Consequently, the conditional additional price of €1.25 per share (linked to reaching the 90% mark) will not be paid to tendering shareholders. Despite remaining listed for the time being, the transaction effectively shifts Eurobio into a "private-equity-backed" development phase, allowing for deeper consolidation of the European in vitro diagnostics market.

EUROBIO SCIENTIFIC, which reported an EBITDA margin of LOGIN in 2024, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN to the average currently observed in the Healthcare & Pharma sector (14.8x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Eurobio Scientific is a leading French player in the field of in vitro diagnostics (IVD) and "intelligent health." The company’s business model is vertically integrated, encompassing the design, development, and commercialization of specialty diagnostic kits alongside the distribution of high-end reagents and equipment for clinical laboratories and research centers. A key pillar of its value proposition is its focus on high-added-value proprietary products, reinforced by strategic acquisitions such as the 2022 purchase of GenDx, a global leader in HLA typing for transplant compatibility. Eurobio Scientific played a critical role in the post-Covid diagnostic landscape by shifting its focus toward proprietary innovation and international expansion. Operating as an "ETI" (Intermediate-Sized Enterprise), the company leverages its deep technical expertise to serve the transplantation, infectious diseases, and oncology markets, aiming to become a pan-European leader in specialized diagnostics.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2024

2023

Similar deals in Healthcare & Pharma

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
02/2025	NOVONESIS	FEED ENZYME ALLIANCE	DENMARK	Life Sciences	This transaction is a strategic corporate carve-out and vertical integration wherein Novonesis fully acquires the sales and distribution activities of the Feed Enzyme Alliance from its long-term joint venture partner, dsm-firmenich
01/2025	QUADRIVIO GROUP	MIR - MEDICAL INTERNATIONAL RESEARCH	ITALY	Life Sciences	The secondary buyout of 100% of Medical International Research by Quadrivio Group triggers the complete exit of the incumbent private equity sponsor Aksìa SGR. This ownership transition follows an operational phase marked by an annualized revenue expansion and the successful launch of subscription-based software services
12/2024	UI INVESTISSEMENT	DIDACTIC	FRANCE	Life Sciences	Didactic reorganized its shareholder base to accelerate its transformation into a European industrial leader. GENEO Capital Entrepreneur and UI Investissement acquired a majority stake, taking over from the previous sponsor
11/2024	NAXICAP PARTNERS	GLOBAL D	FRANCE	Life Sciences	Naxicap Partners has acquired a majority stake (over 60%) in Global D, marking the company’s first independent LBO following its carve-out from the Menix Group. The remaining capital is held by a dozen managers led by the executive team
10/2024	CLAYTON, DUBILIER & RICE (CD&R)	OPELLA	FRANCE	Life Sciences	Sanofi has announced the sale of 50% of its stake in Opella to the American fund CD&R. Opella Healthcare (formerly Sanofi Consumer Healthcare) is a company specializing in consumer healthcare products
10/2024	KKR / KREFELD	ANJAC BEAUTY & HEALTH	FRANCE	Life Sciences	Anjac reorganized its capital by welcoming KKR and Krefeld as minority shareholders, following a competitive process led by Rothschild & Co. The EUR450M investment allowed the exit of historical partners Andera Partners, Bpifrance, and IDIA
10/2024	BANSK GROUP	PETIQ	UNITED STATES	Life Sciences	Bansk Group completed the acquisition of 100% of PetIQ in an all-cash public-to-private transaction. PetIQ was delisted from Nasdaq upon closing and is now operated as a privately held company, with founder Cord Christensen continuing as CEO
09/2024	AGILENT TECHNOLOGIES	BIOVECTRA	CANADA	Life Sciences	Agilent Technologies has finalized the acquisition of BIOVECTRA, a move designed to fundamentally expand the group's contract development and manufacturing (CDMO) portfolio into fast-growing therapeutic modalities
08/2024	RECURSION PHARMACEUTICALS	EXSCIENTIA	UNITED KINGDOM	Life Sciences	Recursion Pharmaceuticals has entered into a definitive agreement to acquire Exscientia in an all-stock transaction. This strategic move aims to bring together two artificial intelligence-driven drug discovery specialists, creating a comprehensive platform that spans the entire process, from biology to computational chemistry
08/2024	NORDSON CORPORATION	ATRION CORPORATION	UNITED STATES	Life Sciences	Nordson Corporation completed its acquisition of Atrion Corporation on August 21, 2024, following the definitive agreement announced on May 28, 2024. The strategic rationale is centered on portfolio expansion within Nordson Medical

REFERENCES

Valuation range: EV 100M - 350M EUR

Revenue range: 100M - 200M EUR

EBITDA range: 5M - 25M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of EUROBIO SCIENTIFIC by NEXTSTAGE / IK PARTNERS are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Press release: view release

Acquirer: nextstage / ik partners